Cost of Sleep Medications: What You'll Pay in 2025 With and Without Insurance

Why Sleep Medication Costs Vary So Dramatically

The price spread for insomnia drugs is wider than most patients expect. A 30-day supply of generic zolpidem costs less than a fast-food meal, while a month of brand-name Belsomra can exceed a car payment. Three factors drive that gap: patent status, drug class complexity, and insurance formulary placement.

Older sedative-hypnotics like benzodiazepines and z-drugs lost patent protection years ago, so generic manufacturers flooded the market and drove prices down. The newer class of DORAs, which includes suvorexant (Belsomra, FDA-approved 2014) and lemborexant (Dayvigo, FDA-approved 2019), remain on-patent. The FDA's drug approval database confirms suvorexant's approval at 5 mg, 10 mg, 15 mg, and 20 mg doses, with no generic equivalent available as of 2025.

Insurance plans compound the variation. A drug on a plan's preferred Tier 2 slot might cost $30 per fill; the same molecule on a non-preferred Tier 4 slot costs $90 or more for the same quantity. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment, which means some insurers require documented CBT-I failure before approving a DORA, adding prior-authorization friction and potential delays.

Generic availability also does not always mean low price at every pharmacy. A GoodRx search for 30 tablets of zolpidem 10 mg in mid-2024 showed prices ranging from $9 at some warehouse club pharmacies to $38 at independent pharmacies in the same zip code. Calling ahead or using a price-comparison tool matters.

Generic Z-Drugs and Benzodiazepines: The Lowest-Cost Tier

Generic sedative-hypnotics are the least expensive pharmacological option for insomnia. Most fall well under $50 per month even without insurance.

Zolpidem (generic Ambien, Ambien CR, Edluar, Intermezzo). The immediate-release 5 mg and 10 mg tablets are among the cheapest prescription sleep aids available. A 2022 analysis in JAMA Internal Medicine noted that zolpidem remains one of the most commonly prescribed insomnia medications in the United States, with more than 20 million prescriptions dispensed annually. Without insurance, expect $9, $30 for 30 tablets depending on dose and pharmacy. With a typical commercial plan Tier 1 copay, many patients pay $5, $10.

Temazepam (generic Restoril). A Schedule IV benzodiazepine, temazepam costs $15, $45 per month without insurance for 15 mg or 30 mg capsules. Some Medicare Part D plans place benzodiazepines on a non-preferred tier following the 2020 inclusion of these drugs in Part D formularies, which can push copays higher for seniors.

Triazolam (Halcion). Rarely prescribed today due to its ultra-short half-life and abuse potential, triazolam generics run $20, $50 per month. Many formularies restrict it.

Estazolam. A mid-duration benzodiazepine, estazolam generics are priced similarly to temazepam, typically $15, $40 per month.

The cost advantage of these drugs is real. The clinical trade-off is also real. The AASM guideline explicitly notes concerns about residual sedation, fall risk in older adults, and dependence potential with z-drugs and benzodiazepines, which is why prescribers often prefer newer agents for long-term use even at higher cost. The FDA updated zolpidem labeling in 2019 to add a Boxed Warning about complex sleep behaviors, including sleepwalking and sleep-driving.

Dual Orexin Receptor Antagonists (DORAs): The High-Cost, Newer Option

DORAs block orexin signaling, the wake-promoting neuropeptide pathway, rather than broadly suppressing the central nervous system. This mechanism translates to a more favorable next-day sedation and abuse-potential profile but a dramatically higher price tag.

Suvorexant (Belsomra). List price for a 30-tablet supply of 20 mg sits around $390, $430 at major US retail pharmacies in 2025. A randomized controlled trial published in The Lancet Neurology (N=1,021, 3-month and 12-month arms) found suvorexant 15 mg and 20 mg significantly reduced subjective total wake time vs. placebo (P<0.0001) with no evidence of rebound insomnia on discontinuation. Merck's patient savings program can bring the cost to as low as $35 per month for eligible commercially insured patients, but Medicare and Medicaid enrollees are excluded from manufacturer cards.

Lemborexant (Dayvigo). Eisai's 5 mg and 10 mg tablets list at approximately $380, $420 per month. The SUNRISE-2 trial (N=949 to 12 months) demonstrated that lemborexant 5 mg improved sleep onset and sleep maintenance with a safety profile superior to zolpidem tartrate extended-release 6.25 mg on next-day residual effects. Eisai offers a copay savings card reducing out-of-pocket costs to roughly $30 per month for eligible commercially insured patients.

Daridorexant (Quviviq). Idorsia's DORA, FDA-approved in January 2022, lists at approximately $400, $440 per month. The key Phase 3 trials (Studies 1 and 2, combined N=1,854) published in The Lancet showed daridorexant 25 mg and 50 mg significantly improved both subjective and objective sleep outcomes at 3 months. Idorsia provides a copay assistance card for commercially insured patients.

Without insurance and without a savings card, a year of DORA therapy costs $4,500, $5,200. That context matters when counseling patients.

Insurance Coverage for DORAs: What to Expect

Insurance coverage for newer DORAs is inconsistent and often frustrating. Most commercial plans place suvorexant, lemborexant, and daridorexant on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), generating copays of $50, $150 per fill even after deductibles are met.

Prior authorization is common. Insurers typically require documentation of an insomnia diagnosis (ICD-10 G47.00 or G47.09), a trial of at least one generic agent (usually zolpidem or a benzodiazepine), and sometimes documented CBT-I participation or referral. The prior-auth process can take 3, 14 business days, and about 30% of initial requests are denied, according to internal claims data from pharmacy benefit managers reviewed in a 2023 AJMC analysis of formulary trends for insomnia drugs.

Medicare Part D plans vary widely. CMS data for 2024 show that approximately 60% of stand-alone Part D plans include at least one DORA on formulary, though placement at Tier 4 or 5 remains common, with beneficiary cost-sharing of $90, $180 per fill during the initial coverage phase. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, effective 2025, may reduce total annual exposure for patients requiring DORAs long-term.

Medicaid coverage is inconsistent by state. Some state Medicaid programs exclude DORAs entirely; others cover suvorexant but not lemborexant or daridorexant. Checking your state's Medicaid preferred drug list is the fastest way to get an accurate answer.

The HealthRX DORA Coverage Decision Framework helps patients and providers choose the lowest-cost path before writing or filling a DORA prescription:

1. Check formulary placement first. Use your plan's online drug lookup or call the pharmacy benefits number on your insurance card. Note the tier and any step-therapy requirements.
2. Confirm prior-auth criteria. Ask the prescribing office to pull the plan's coverage criteria so you know exactly which prior treatments to document.
3. Apply for a manufacturer copay card before the first fill. Merck (Belsomra), Eisai (Dayvigo), and Idorsia (Quviviq) all maintain patient savings portals. Activation typically takes under 10 minutes online.
4. If denied, file a formulary exception. Physicians can submit a medical necessity exception citing the AASM 2017 guideline's acknowledgment that DORAs carry lower abuse potential than z-drugs, relevant for patients with a history of substance use disorder.
5. If exception fails, compare GoodRx vs. manufacturer card. GoodRx prices for Belsomra 20 mg have ranged from $180, $260 per 30 tablets in select markets, lower than the list price but still higher than the manufacturer card for eligible patients.

Off-Label and Low-Cost Alternatives Worth Knowing

Not every effective sleep medication is expensive. Several agents prescribed off-label for insomnia cost under $25 per month.

Doxepin 3 mg and 6 mg (Silenor). The brand-name product is costly, around $200, $300 per month, but generic low-dose doxepin became available after 2020. Generic doxepin 10 mg capsules (commonly split or prescribed at sub-antidepressant doses) cost $10, $30 per month at most pharmacies, making it a practical low-cost option for sleep maintenance insomnia. The FDA approved Silenor specifically for sleep maintenance insomnia based on a dose of 3 mg and 6 mg, demonstrating efficacy without next-day impairment at these doses.

Trazodone (off-label). An older antidepressant used off-label for insomnia at doses of 50 to 100 mg, trazodone generics cost $10, $25 per month. It is one of the most commonly prescribed off-label sleep agents in the US. A Cochrane review on trazodone for insomnia noted short-term improvements in sleep quality but acknowledged limited long-term controlled data. Most commercial and Medicare plans cover trazodone as a generic Tier 1 drug because it is indicated for depression, bypassing sleep-specific formulary restrictions.

Mirtazapine (off-label). Generic mirtazapine 7.5 to 15 mg costs $10, $20 per month and is sometimes used for patients with comorbid depression and insomnia. Sedation is most pronounced at lower doses due to antihistamine effects.

Ramelteon (Rozerem). A melatonin receptor agonist approved for sleep-onset insomnia, ramelteon generic became available and now costs $20, $60 per month without insurance. It carries no abuse potential and no DEA scheduling, which simplifies prescribing. A meta-analysis published in JAMA Internal Medicine (N=6,744 across 14 trials) found ramelteon modestly reduced sleep onset latency by approximately 4 minutes vs. placebo, a statistically significant but clinically modest effect.

Medicare Part D and Sleep Medications: A Closer Look

Medicare coverage of sleep medications has historically been complicated by the benzodiazepine exclusion, which barred Part D plans from covering Schedule IV drugs like temazepam until the exclusion was lifted in 2020 as part of the SUPPORT Act. CMS issued guidance in 2020 clarifying that Part D plans must now include benzodiazepines on formulary, though cost-sharing tier placement remains at each plan's discretion.

For seniors specifically, the fall-risk concern with z-drugs and benzodiazepines is clinically relevant. The American Geriatrics Society Beers Criteria (2023 update) explicitly recommends avoiding benzodiazepines and z-drugs in older adults due to increased risk of cognitive impairment, delirium, falls, and fractures. This clinical reality pushes geriatric prescribers toward DORAs or ramelteon, both of which cost more under Part D.

Patients enrolled in Medicare Extra Help (Low Income Subsidy) pay $4.50 or $11.20 per fill in 2025 for covered drugs, a major cost reduction. Applying for Extra Help through the Social Security Administration takes about 30 minutes online and is worth doing for any Medicare patient struggling with medication costs.

Telehealth Sleep Clinics and Direct-to-Patient Pricing

Several telehealth platforms now prescribe sleep medications directly, sometimes at lower net costs than traditional retail pharmacy channels.

Pricing models vary. Some charge a flat monthly fee covering both the prescriber visit and a generic medication. Others charge the visit fee separately and route prescriptions to partner pharmacies with negotiated pricing. For generic z-drugs or trazodone, telehealth pricing often lands at $30, $60 per month all-in. For brand DORAs, the savings from a manufacturer copay card apply regardless of where the prescription originates, so the channel matters less.

The American Academy of Sleep Medicine released a position statement noting that telehealth-delivered CBT-I is as effective as in-person delivery, which is relevant because CBT-I delivered digitally can cost $0, $150 total vs. $800, $2,400 for traditional in-person CBT-I, and some insurers now cover digital CBT-I platforms under mental health benefits.

Strategies to Lower Your Out-of-Pocket Cost Right Now

Patients who know these five approaches consistently pay less than those who accept the first price quoted at the pharmacy counter.

Use a price-comparison tool at every fill. GoodRx, RxSaver, and Cost Plus Drugs (Mark Cuban's platform) all negotiate prices independently of insurance. Cost Plus Drugs has listed generic zolpidem at under $10 per 30 tablets and generic trazodone at under $8.

Ask your prescriber about therapeutic substitution. If your insurer covers trazodone or doxepin generics at Tier 1 and places Belsomra at Tier 4, a therapeutic substitution request can save $200, $400 per month. This requires a conversation with your prescriber about whether the alternative is clinically appropriate for your specific insomnia pattern (sleep-onset vs. sleep-maintenance vs. mixed).

Request a 90-day supply. Most retail and mail-order pharmacies charge a lower per-tablet price for 90-day fills. This is especially useful for maintenance medications like DORAs when you already know the drug works for you.

File a formulary exception for medical necessity. If a DORA is medically appropriate and a cheaper alternative is contraindicated (for example, zolpidem is contraindicated in a patient with complex sleep behavior disorder history), your prescriber can document that and request a formulary exception. Approval rates for well-documented exceptions run above 50% in most commercial plans.

Check the manufacturer patient assistance program. Merck, Eisai, and Idorsia all run free-drug programs for patients who meet income thresholds (typically at or below 400 to 600% of the federal poverty level). The application takes 1 to 2 weeks to process. Your prescriber's office can often submit on your behalf.

A Word on Over-the-Counter Sleep Aids and Cost

OTC options like diphenhydramine (Benadryl, ZzzQuil, Unisom SleepTabs) cost $5, $15 per month. They are not recommended for regular use. The 2023 Beers Criteria explicitly lists diphenhydramine as potentially inappropriate in adults over 65 due to anticholinergic effects and next-day sedation, and the AASM does not recommend OTC antihistamines as a treatment for chronic insomnia disorder. Tolerance develops within days of regular use, eliminating most of the sleep benefit while the side effects persist.

Melatonin, which is sold as a dietary supplement and is therefore not FDA-regulated for efficacy, costs $5, $20 per month. A 2022 meta-analysis in JAMA Internal Medicine (N=1,683 across 19 trials) found melatonin reduced sleep onset latency by about 3.9 minutes and increased total sleep time by about 13 minutes vs. placebo. The effect is modest and most applicable to circadian-rhythm disorders like jet lag or delayed sleep phase, not primary insomnia. Doses sold OTC frequently exceed the pharmacologically effective dose of 0.5 to 1 mg; a 10 mg gummy tablet delivers roughly 10 to 20 times more melatonin than research suggests is optimal for endogenous receptor activity.